Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights


Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing prescription drug approvals. Its technologies and research capabilities contributed the development of a diversified portfolio of biotechnology and pharmaceutical products for arrhythmia, infectious, inflammatory, metabolic, respiratory and genetic diseases, arrhythmia, central nervous system, oncology, ophthalmology, hematology, menopause, musculoskeletal disorder, multiple myeloma, osteoporosis, and among others. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc Key Recent Developments

May 06,2020: Ligand reports first quarter 2020 financial results
Apr 06,2020: Ligand provides a corporate update and announces May 6th as the date for first quarter earnings call
Mar 10,2020: Ligand’s presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com
Feb 27,2020: Ligand raises 2020 financial guidance due to higher captisol material sales
Feb 06,2020: Ligand reports fourth quarter and full year 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Ligand Pharmaceuticals Inc - Key Facts
Ligand Pharmaceuticals Inc - Key Employees
Ligand Pharmaceuticals Inc - Key Employee Biographies
Ligand Pharmaceuticals Inc - Major Products and Services
Ligand Pharmaceuticals Inc - History
Ligand Pharmaceuticals Inc - Company Statement
Ligand Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ligand Pharmaceuticals Inc - Business Description
Ligand Pharmaceuticals Inc - Corporate Strategy
Ligand Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Ligand Pharmaceuticals Inc - Strengths
Ligand Pharmaceuticals Inc - Weaknesses
Ligand Pharmaceuticals Inc - Opportunities
Ligand Pharmaceuticals Inc - Threats
Ligand Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ligand Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 06, 2020: Ligand reports first quarter 2020 financial results
Apr 06, 2020: Ligand provides a corporate update and announces May 6th as the date for first quarter earnings call
Mar 10, 2020: Ligand’s presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com
Feb 27, 2020: Ligand raises 2020 financial guidance due to higher captisol material sales
Feb 06, 2020: Ligand reports fourth quarter and full year 2019 financial results
Feb 03, 2020: Ligands technologies support and enable potential Coronavirus treatments
Nov 05, 2019: Ligand reports third quarter 2019 financial results
Oct 15, 2019: Ligand appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Jul 30, 2019: Ligand Reports Second Quarter 2019 Financial Results
May 02, 2019: Ligand reports first quarter 2019 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Ligand Pharmaceuticals Inc, Key Facts
Ligand Pharmaceuticals Inc, Key Employees
Ligand Pharmaceuticals Inc, Key Employee Biographies
Ligand Pharmaceuticals Inc, Major Products and Services
Ligand Pharmaceuticals Inc, History
Ligand Pharmaceuticals Inc, Subsidiaries
Ligand Pharmaceuticals Inc, Key Competitors
Ligand Pharmaceuticals Inc, Ratios based on current share price
Ligand Pharmaceuticals Inc, Annual Ratios
Ligand Pharmaceuticals Inc, Annual Ratios (Cont...1)
Ligand Pharmaceuticals Inc, Annual Ratios (Cont...2)
Ligand Pharmaceuticals Inc, Interim Ratios
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ligand Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Ligand Pharmaceuticals Inc, Performance Chart (2015 - 2019)
Ligand Pharmaceuticals Inc, Ratio Charts
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Ligand Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Ligand Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Ligand Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

USD 125 View Report

Rocket Pharmaceuticals Inc (RCKT) - Financial and Strategic SWOT Analysis Review

Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapeutics for the treatment of glaucoma and

USD 300 View Report

Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review

Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available